Clinical data | |
---|---|
Routes of administration | Oral |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H20N4O2 |
Molar mass | 300.362 g·mol−1 |
3D model (JSmol) | |
| |
|
BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. It interacts with the human endocannabinoid system.[1] The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity.[2] A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man.[1][3][4][5] The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown.[6][7]
Bialstatement
was invoked but never defined (see the help page).ANSM Statement
was invoked but never defined (see the help page).Ministry Statement
was invoked but never defined (see the help page).Rennes2
was invoked but never defined (see the help page).ANSMfinal
was invoked but never defined (see the help page).Hinnerk
was invoked but never defined (see the help page).